Company Filing History:
5 out of 64 
1 out of 17 
1 out of 576 
Years Active: 1997-2015
Title: Innovations in Vaccine Development by Gary G Hermanson
Introduction
Gary G Hermanson is a notable inventor based in Encinitas, CA, who has made significant contributions to the field of vaccine development. With a total of 7 patents to his name, Hermanson's work primarily focuses on polynucleotide-based vaccines aimed at combating human cytomegalovirus (HCMV) infections. His innovative approaches have the potential to enhance immune responses and improve vaccine efficacy.
Latest Patents
One of Hermanson's latest patents involves codon-optimized polynucleotide-based vaccines against HCMV infection. This invention relates to plasmids that encode HCMV antigens, which have been modified for improved translation in human and other mammalian cells through codon optimization. The HCMV antigens utilized in this invention include pp65, glycoprotein B (gB), and IE1, along with their fragments, variants, or derivatives. The patent also outlines methods for inducing an immune response to HCMV in mammals, including humans, by delivering a plasmid encoding a codon-optimized HCMV antigen. Additionally, the invention encompasses pharmaceutical compositions that include these plasmids along with adjuvants, excipients, or immune modulators.
Career Highlights
Throughout his career, Gary G Hermanson has worked with prominent companies in the biotechnology sector, including Vical Incorporated and Epimmune Inc. His experience in these organizations has contributed to his expertise in vaccine development and immunology.
Collaborations
Hermanson has collaborated with notable professionals in the field, including Andrew John Geall and Mary Kopke Wloch. These partnerships have likely enriched his research and innovation efforts.
Conclusion
Gary G Hermanson's contributions to vaccine development, particularly in the area of HCMV, highlight his role as a leading inventor in the biotechnology field. His innovative approaches and collaborations continue to pave the way for advancements in immunology and vaccine efficacy.